Genes on Y chromosome protect against pulmonary hypertension, study suggests
This study is the first to examine the involvement of sex chromosomes in the disease's development in the absence of sex hormones. In humans, females typically have two copies of the X chromosome, while males typically have one X and one Y chromosome.METHODIn the lab, the researchers engineered mice with different chromosomal makeups and measured their development of pulmonary hypertension in an environment with 10 percent oxygen, which is a well-established setting for inducing the disease.One group of mice was engineered with sex chromosomes that were independent of their gonadal sex, or sex based on their genitalia, so that the researchers could isolate the impact of sex chromosomes. The other group of mice in the experiment had different variants of sex chromosomes in order for the researchers to determine the impact of the presence of a Y chromosome versus varying numbers of X chromosomes. All the mice had their gonads removed so that the researchers could eliminate the potential effects of sex hormones.The researchers then placed the mice in the 10 percent oxygen environment for three weeks. At the end of the experiment, the researchers examined the hearts and lungs of the mice. Mice with a Y chromosome experienced significantly less severe pulmonary hypertension and were protected against the development of the disease.IMPACTThese findings identify a new avenue for research into effective ways to treat pulmonary hypertension. In the future, determining which genes on t...
Conclusions: In patients with FIP, PVR is a significant contributor of 6MWD, independently from the extent of fibrosis on HRCT. These results strengthen both the rationale to use 6MWD as endpoint in FIP and to target APH with specific therapies.Respiration
ConclusionsPatients with CS have similar post-transplant hemodynamics as patients without CS, without evidence of right ventricular dysfunction or pulmonary hypertension. Neither significant rejection nor recurrence of sarcoid in the allograft was observed in this cohort of patients with CS. Survival is similar between patients with CS and those without CS. Heart transplant is a viable strategy in selected patients with CS with excellent outcomes.RésuméIntroductionLa transplantation cardiaque orthotopique (TCO) est de plus en plus utilisée lors d’insuffisance cardiaque terminale liée &agra...
Repair of Hemi-Truncus with "Irreversible" Pulmonary Hypertension. Ann Thorac Surg. 2018 Jul 13;: Authors: Sha JM, Cao Y, Xu SS Abstract Anomalous origin of the pulmonary artery from the ascending aorta (AOPA) can lead to congestive heart failure in infancy and with advancing age many patients will develop severe pulmonary hypertension. Surgical intervention had high mortality/morbidity risk if this happens. Strategies to manage these patients seem only limited to heart-lung transplantation or lung transplantation. Here, we successfully carried out surgical intervention to in an adult patien...
Despite advances in targeted medical therapy, pulmonary arterial hypertension (PAH) remains a fatal disease because of progressive right ventricular dysfunction. For patients who are refractory to medical therapy, heart-lung and lung transplantation are important treatment options. Because of longer waiting time, surgical interventions including extracorporeal lung support and atrial septostomy can be used in PAH patients bridging to transplantation.
We examined safety and long-term outcomes of intravenous treprostinil administered via the implantable LENUS Pro ® pump in patients with severe pulmonary hypertension (PH).
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare but severe complication of acute pulmonary embolism leading to right heart failure and premature mortality. Its cumulative incidence ranges from 0.1 –9.1% within the first 2 years after symptomatic acute pulmonary embolism, although probably underestimated due to the lack of systematic follow-up and screening in clinical routine.1–3
Chronic thromboembolic pulmonary hypertension (CTEPH) results from persistent pulmonary vascular obstructions, presumably due to inflammatory thrombosis. Because estimates of thrombus volume at diagnosis have no predictive value, we investigated the role of the thrombosis marker D-dimer and the inflammation marker C-reactive protein (CRP) for predicting outcomes in CTEPH.
The pathobiology of chronic thromboembolic pulmonary hypertension (CTEPH) is poorly understood. Metabolic dysregulation is prominent in idiopathic pulmonary arterial hypertension (IPAH). Using an “omics” approach, we sought to determine the metabolic fingerprint of CTEPH patients compared to IPAH and healthy controls.
We hypothesized that dynamic measures of pulmonary arterial compliance (Cpa), and elastance (Epa), RV elastance (Ees), and RV-PA coupling would improve prediction of post-op mean PA pressure (PAP), Length of Stay (LOS), ICU duration (ICUd) and need for inotropes (NFI) compared to prediction based solely on pre-op PAP, CO and PVR in patients with chronic thromboembolic pulmonary hypertension (CTEPH) undergoing pulmonary thromboendaterectomy (PTE).
Exercise right heart catheterization (RHC), currently used to identify occult pulmonary hypertension (PH), may have additional applications. An elevated total pulmonary resistance (TPR), the change in mean pulmonary arterial pressure (mPAP) divided by the change in cardiac output during exercise, has been associated with worse clinical outcomes. We hypothesize that the combination of the TPR and the PCWP during exercise ( ∆TPRex) reflects pulmonary arterial disease and is a marker of outcomes.
More News: Cardiology | Environmental Health | Genetics | Heart | Heart Transplant | Hormones | Hypertension | Lung Transplant | National Institutes of Health (NIH) | Pulmonary Hypertension | Respiratory Medicine | Study | Transplant Surgery | Transplants | Universities & Medical Training | USA Health | Women